Hematologic Malignancies and Stem Cell Transplantation Institute

Hematologic cancers are those cancers that occur in cells of the immune system or in blood-forming tissues including bone marrow. As a pioneer in advancing care for all hematologic cancers and related blood disorders, City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute leads the field as one of the largest and most successful transplant centers in the world.
Led by Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, our dedicated, multidisciplinary team of health care professionals combine innovative research discoveries with superior clinical treatments to improve outcomes for patients with:
  • Leukemia (cancer of the blood cells) at the Gehr Family Center for Leukemia Research
    • Acute myeloid leukemia
    • Acute lymphoblastic leukemia
    • Chronic myelogenous leukemia
    • Chronic lymphocytic leukemia
  • Lymphoma (cancer of the lymphatic cells) at the Toni Stephenson Lymphoma Center
    • Hodgkin lymphoma
    • Non-Hodgkin lymphoma
  • Myeloma (cancer of plasma cells) at the Judy and Bernard Briskin Center for Multiple Myeloma Research
  • Myelodysplastic Syndrome (blood abnormalities that can be life-threatening or lead to cancer)
  • Other hematologic disorders
In addition to the three named centers above, the institute also houses the Center for Gene Therapy and the Immunology Center, both focused on discovering and improving treatments against hematologic disorders.
  • The Center for International Blood and Marrow Transplant Research Center has ranked City of Hope as an “over-performing” transplant center, and City of Hope is the only U.S. transplant center with this recognition for ten consecutive years.
  • City of Hope recognizes the importance of maintaining contact with all transplant patients to ensure they have optimal outcomes after their treatment have concluded. Established in 1998, our Long-term Follow-up Program follows all patients who have received a transplant at City of Hope. Through this program, our survivors can be carefully monitored for long-term effects and given timely interventions, while our clinicians and researchers have access to data that can be used to further improve cancer treatments.
  • City of Hope's hematology malignancy program integrates both transplant and non-transplant therapies, so there is a smoother transition of treatments for patients who ultimately need a stem cell transplant.
  • City of Hope physicians have extensive experience performing a wide variety of transplant procedures, having performed more than 12,000 transplants—one of the biggest programs in the United States. Our expertise includes both autologous and allogeneic stem cell transplants (using cells directly from the patient and from another person, respectively), using cells derived from bone marrow, peripheral blood and cord blood.
  • City of Hope’s transplant program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), the standard of excellence for blood and bone marrow transplant programs in the United States.
As one of a select number of institutes to attain the elite designation of Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment and U.S. News & World Report has named City of Hope one of the top cancer hospitals in America.

If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.